NCT03874923

Brief Summary

The objective of fluid challenge is to increase oxygen delivery (DO2) in order to improve/restore tissue oxygen consumption (VO2). However the fluid challenge volume to administer stills in debate, some studies recommend to administer 250 mL. Previous studies suggested that 500 mL of fluid challenge administration may improve cardiac output and oxygen delivery. The relation between the amount of fluid expansion and oxygen delivery and oxygen consumption was not yet been studied in a randomized study in critical care patients. This is the purpose of this study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 14, 2019

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 24, 2021

Completed
2.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2023

Completed
Last Updated

August 8, 2025

Status Verified

August 1, 2025

Enrollment Period

2.2 years

First QC Date

March 7, 2019

Last Update Submit

August 7, 2025

Conditions

Keywords

fluid expansionoxygen deliverytissue perfusioncardiac output

Outcome Measures

Primary Outcomes (2)

  • VO2 after fluid challenge

    Tissue oxygen consumption (VO2) after fluid challenge

    30 minutes after fluid challenge.

  • VO2 after fluid challenge

    Tissue oxygen consumption (VO2) after fluid challenge

    60 minutes after fluid challenge.

Secondary Outcomes (8)

  • Change of arterial lactate concentration from baseline

    30 minutes after fluid challenge.

  • Change of arterial lactate concentration from baseline

    60 minutes after fluid challenge.

  • Respiratory variation of stroke volume

    Immediately, 30 and 60 minutes after fluid challenge.

  • PaO2/FiO2

    Immediately, 30 and 60 minutes after fluid challenge.

  • Respiratory variation of the pulse pressure

    30 and 60 minutes after fluid challenge.

  • +3 more secondary outcomes

Study Arms (2)

250 mL of fluid challenge

ACTIVE COMPARATOR
Other: Fluid challenge

500 mL of fluid challenge

EXPERIMENTAL
Other: Fluid challenge

Interventions

After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.

250 mL of fluid challenge500 mL of fluid challenge

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient for whom the physician in charge decided to infuse fluid challenge because of signs of acute circulatory failure (systolic arterial blood pressure \< 90mmHg, and/or mean arterial blood pressure\< 65 mmHg, and/or the need of vasopressive amine infusion, and/or skin mottling, and/or diuresis \<0.5 mL/kg/h for more than 2 hours, and/or arterial lactate level\>2mmol/L.
  • Echogenic patient
  • Patient with a Stroke Volume (SV) variation with passive leg raising (PLR) more than 10%.
  • Patient with regular sinus rhythm.
  • Patient who received protocol information.

You may not qualify if:

  • Age Under 18-year-old.
  • Pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens Picardie

Amiens, France

Location

Study Officials

  • Osama Abou-Arab, Dr

    CHU Amiens

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2019

First Posted

March 14, 2019

Study Start

March 1, 2019

Primary Completion

May 24, 2021

Study Completion

August 30, 2023

Last Updated

August 8, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations